Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Conditions
- Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Interventions
- DRUG: nalfurafine hydrochloride (TRK-820)
- DRUG: Placebo
Sponsor
SK Chemicals Co., Ltd.
Collaborators